Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Bing-He Xu"'
Autor:
Yi‐Kun Kang, Yi‐Ran Si, Jie Ju, Zhu‐Qing Jia, Nan‐Lin Hu, Hao Dong, Xue Wang, Jian Yue, Pei‐Di Jiang, Zhao‐Liang Li, Yun‐Yun Zhang, Yan Wang, Bing‐He Xu, Peng Yuan
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5323-5333 (2023)
Abstract Background Early prediction of treatment response is crucial for the optimal treatment of advanced breast cancer. We aimed to explore whether monitoring early changes in plasma human epidermal growth factor receptor 2 (HER2) levels using dig
Externí odkaz:
https://doaj.org/article/9851eead41c14b3f967b0cfd6750234a
Autor:
Chun-Xiao Li, Jin-Song Wang, Wen-Na Wang, Dong-Kui Xu, Yan-Tong Zhou, Fang-Zhou Sun, Yi-Qun Li, Feng-Zhu Guo, Jia-Lu Ma, Xue-Yan Zhang, Meng-Jiao Chang, Bing-He Xu, Fei Ma, Hai-Li Qian
Publikováno v:
Military Medical Research, Vol 9, Iss 1, Pp 1-16 (2022)
Abstract Background The cell cycle is at the center of cellular activities and is orchestrated by complex regulatory mechanisms, among which transcriptional regulation is one of the most important components. Alternative splicing dramatically expands
Externí odkaz:
https://doaj.org/article/0b101f76a852485bb492a0a9278af79d
Autor:
Jin-Hu Fan, Su Zhang, Huan Yang, Zong-Bi Yi, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E. Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xue-Nong Ouyang, Jian-Jun He, Xin-Lan Liu, Shun-E. Yang, Jia-Yu Wang, Bing-He Xu, You-Lin Qiao
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThis study aimed to explore possible associations between molecular subtypes and site of distant metastasis in advanced breast cancer (ABC).Methods3577 ABC patients were selected from 21 hospitals of seven geographic regions in China from 20
Externí odkaz:
https://doaj.org/article/d59fc4f00f5042a8a6ce6d73845e9301
Impact of coronavirus disease 2019 on the clinical diagnosis and treatment of breast cancer in China
Autor:
Yi-Ran Si, Feng Du, Nan-Lin Hu, Xue Wang, Jian Yue, Pei-Di Jiang, Bing-He Xu, Peng Yuan, Li-Shao Guo, the Breast Cancer Group, Chinese Association for Clinical Oncologist
Publikováno v:
Chinese Medical Journal, Vol 134, Iss 5, Pp 590-592 (2021)
Externí odkaz:
https://doaj.org/article/4b51ac0e3d9443a5ad98bb53ba3e7b24
Publikováno v:
Chinese Journal of Cancer, Vol 35, Iss 1, Pp 1-7 (2016)
Abstract Background Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing re
Externí odkaz:
https://doaj.org/article/bf5d462f04924360bae25a97f66d5209
Publikováno v:
Cancer Biology & Medicine, Vol 7, Iss 1, Pp 7-11 (2010)
OBJECTIVE In China, vinorelbine plus an anthracycline is a common neoadjuvant regimen for locally-advanced breast cancer (LABC). Pegylated liposomal doxorubicin (PLD) is an alternate anthracycline formulation with a more favorable safety profi le co
Externí odkaz:
https://doaj.org/article/aa33319ee92f449fb905c56afcf29b6a
Autor:
Jie Ju, Feng Du, Song-Lin Gao, Yi-Ran Si, Nan-Lin Hu, Dong-Xu Liu, Xue Wang, Jian Yue, Fang-Chao Zheng, Yi-Kun Kang, Zi-Xuan Yang, Fei Ma, Bing-He Xu, Peng Yuan
Publikováno v:
Breast Cancer Research and Treatment. 194:221-230
Hormone receptor-positive and human epidermal growth factor receptor 2-positive (HR+/HER2+ breast cancer comprise approximately 5-10% of all invasive breast cancers. However, the lack of knowledge regarding the complexity of tumor heterogeneity in HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d231a192c8a5095a5d461b8ab8938f1
https://doi.org/10.1007/s10549-022-06629-w
https://doi.org/10.1007/s10549-022-06629-w
Autor:
Yi‐Kun Kang, Yi‐Ran Si, Jie Ju, Zhu‐Qing Jia, Nan‐Lin Hu, Hao Dong, Xue Wang, Jian Yue, Pei‐Di Jiang, Zhao‐Liang Li, Yun‐Yun Zhang, Yan Wang, Bing‐He Xu, Peng Yuan
Publikováno v:
Cancer medicineREFERENCES.
Early prediction of treatment response is crucial for the optimal treatment of advanced breast cancer. We aimed to explore whether monitoring early changes in plasma human epidermal growth factor receptor 2 (HER2) levels using digital PCR (dPCR) coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25dee14bebd96d5d50ece788378c747d
https://pubmed.ncbi.nlm.nih.gov/36281495
https://pubmed.ncbi.nlm.nih.gov/36281495
Autor:
Nanlin Hu, Dong-Xu Liu, Peng Yuan, Yi-Kun Kang, Xue Wang, Fei Ma, Yiran Si, Fangchao Zheng, Songlin Gao, Bing-He Xu, Jie Ju, Zixuan Yang, Feng Du, Jian Yue
BackgroundHormone receptor-positive and human epidermal growth factor receptor-2-positive (HR+/HER2+) breast cancer comprise approximately 5-10% of all invasive breast cancers. However, the lack of knowledge regarding the complexity of tumor heteroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d59f36af5d38491d0e9b514cce94c653
https://doi.org/10.21203/rs.3.rs-727627/v2
https://doi.org/10.21203/rs.3.rs-727627/v2
Autor:
Huan Yang, Qu-Chang Ouyang, Min Yan, Xiao-Jia Wang, Xi-Chun Hu, Ze-Fei Jiang, Tao Huang, Zhong-Sheng Tong, Shu-Sen Wang, Yong-Mei Yin, Hui Li, Run-Xiang Yang, Hua-Wei Yang, Yue-E Teng, Tao Sun, Li Cai, Hong-Yuan Li, Xue-Nong Ouyang, Jian-Jun He, Xin-Lan Liu, Shun-E Yang, Jin-Hu Fan, Jia-Yu Wang, You-Lin Qiao, Bing-He Xu
Publikováno v:
Annals of translational medicine. 10(15)
Several studies have indicated possible associations between age and the prognosis of breast cancer (BC), but limited data are available from hospital-based multicenter studies in China. This study aimed to explore the associations between age at ini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd0b62f4bbec8801b9976d75a0c39ce
https://pubmed.ncbi.nlm.nih.gov/36034985
https://pubmed.ncbi.nlm.nih.gov/36034985